Literature DB >> 6616426

Cooperative groups and community hospitals. Measurement of impact in the community hospitals.

C B Begg, M Zelen, P P Carbone, E T McFadden, H Brodovsky, P Engstrom, A Hatfield, J Ingle, B Schwartz, L Stolbach.   

Abstract

The Eastern Cooperative Oncology Group, composed of major cancer treatment centers, has an outreach program which involves community hospitals in ongoing cancer clinical trials. A prevalence survey was carried out in February 1981 among 104 community hospitals and 21 member institutions to determine the characteristics of patients being treated, their staffing, and reasons why patients were not on protocol studies. The survey sampled 25 (50) consecutive patients from community hospitals (member institutions). The purpose of the study was to assess the impact of a community cancer control program. The results of the study demonstrated that 16% of patients surveyed in the affiliated community hospitals were being treated on a research protocol. In addition, a further 35% had their treatment plan influenced by a protocol. Consequently protocols have impacted directly or indirectly on 51% of the patients. The corresponding figures in member institutions were 23% and 38% for a total of 61%. In studying protocol availability, it was found that 66% of all patients were ineligible for any protocol. Of patients eligible for a protocol but not registered on one, 52% were not registered because of physician preference for a specific treatment. The affiliates surveyed were shown to be on average half as large as member institutions in terms of number of beds and staff size. Also, staff/patient ratios are generally smaller in the community hospitals. The median age of patients was considerably lower than SEER incidence data. Also, elderly patients were slightly more prevalent in community hospitals than in member institutions. A clear relationship between disease stage and age in breast cancer patients was noted with the representation of early-stage disease much higher in young women.

Entities:  

Mesh:

Year:  1983        PMID: 6616426     DOI: 10.1002/1097-0142(19831101)52:9<1760::aid-cncr2820520934>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Evaluating productivity in clinical research programs: the National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP).

Authors:  D M Hynes; C P McLaughlin; A D Kaluzny; L P Ford; E Sondik
Journal:  J Med Syst       Date:  1992-12       Impact factor: 4.460

2.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.

Authors:  Joseph M Unger; Elise Cook; Eric Tai; Archie Bleyer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

3.  Is surgical management compromised in elderly patients with breast cancer?

Authors:  H J Wanebo; B Cole; M Chung; M Vezeridis; B Schepps; J Fulton; K Bland
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Authors:  Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

5.  Factors that influence clinical trial participation by patients with cancer in Australia: a scoping review protocol.

Authors:  Kyung Ha You; Zarnie Lwin; Elizabeth Ahern; David Wyld; Natasha Roberts
Journal:  BMJ Open       Date:  2022-04-06       Impact factor: 2.692

6.  Addressing the Barriers to Clinical Trials Accrual in Community Cancer Centres Using a National Clinical Trials Navigator:A Cross-Sectional Analysis.

Authors:  Caroline Hamm; Dora Cavallo-Medved; Devinder Moudgil; Lee McGrath; John Huang; Yueyang Li; Tyler W Stratton; Tyler Robinson; Krista Naccarato; Stephen Sundquist; Janet Dancey
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

7.  The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group.

Authors:  L C Ward; J W Fielding; J A Dunn; K A Kelly
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.